Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04528641
Recruitment Status : Completed
First Posted : August 27, 2020
Results First Posted : February 8, 2022
Last Update Posted : February 8, 2022
Sponsor:
Collaborator:
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Information provided by (Responsible Party):
ReiThera Srl

Brief Summary:
RT-CoV-2 is a Phase I, open-label, dose escalation multicenter clinical trial to assess safety and immunogenicity of the candidate Coronavirus disease (COVID-19) vaccine GRAd-COV2 in Italian healthy volunteers aged 18-55 years and 65-85 years inclusive. GRAd-COV2 is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 Spike protein.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: GRAd-COV2 Phase 1

Detailed Description:

RT-CoV-2 is a Phase I, open-label, dose escalation multicenter clinical trial to assess safety and immunogenicity of the candidate Coronavirus disease (COVID-19) vaccine GRAd-COV2 in Italian healthy volunteers aged 18-55 years and 65-85 years inclusive. GRAd-COV2 is based on a novel replication defective Gorilla Adenovirus and encodes for SARS-COV-2 full length prefusion stabilized Spike protein. GRAd-COV2 is developed and manufactured by ReiThera Srl.

This study will evaluate a singular intramuscular administration of GRAd-COV2 at 3 dose levels: 5e10, 1e11, 2e11viral particles (vp). There will be 6 study arms for a total of 90 healthy volunteers, divided into 2 cohorts of age, 18-55y and 65-85y, respectively.

Participants will be followed up for 24 weeks after vaccination. Follow up includes safety and immunogenicity assessment. Follow up visits will occur at day2, then 1, 2, 4, 8, 12, 24 weeks after vaccination.

The primary objective is to evaluate the safety and reactogenicity of a single dose vaccination schedule of GRAd-COV2 across 3 dosages in healthy younger and older adults. The secondary objective is to evaluate humoral and cellular immunogenicity.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 98 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase I, open-label, dose escalation, clinical trial to assess the safety and immunogenicity of the candidate GRAd-COV2 vaccine in 90 healthy volunteers aged 18-55 years and elderly volunteers aged 65-85 years. The vaccine will be administered intramuscularly once in time.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects
Actual Study Start Date : August 10, 2020
Actual Primary Completion Date : May 19, 2021
Actual Study Completion Date : May 19, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Arm 1 - Low dose
Arm-1 Healthy adult volunteers aged 18-55y will receive IM single dose of 5e10vp. N=15
Biological: GRAd-COV2
Single intramuscular administration.

Experimental: Arm 2 - Intermediate dose
Arm-2 Healthy adult volunteers aged 18-55y will receive IM single dose of 1e11vp. N=15
Biological: GRAd-COV2
Single intramuscular administration.

Experimental: Arm 3 - High dose
Arm-3 Healthy adult volunteers aged 18-55y will receive IM single dose of 2e11vp. N=15
Biological: GRAd-COV2
Single intramuscular administration.

Experimental: Arm 4 - Low dose
Arm-4 Healthy elderly volunteers aged 65-85y will receive IM single dose of 5e10vp. N=16
Biological: GRAd-COV2
Single intramuscular administration.

Experimental: Arm 5 - Intermediate dose
Arm-5 Healthy elderly volunteers aged 65-85y will receive IM single dose of 1e11vp. N=15
Biological: GRAd-COV2
Single intramuscular administration.

Experimental: Arm 6 - High dose
Arm-6 Healthy elderly volunteers aged 65-85y will receive IM single dose of 2e11vp. N=15
Biological: GRAd-COV2
Single intramuscular administration.




Primary Outcome Measures :
  1. Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination [ Time Frame: 7 days following the vaccination ]
    Participants were monitored for 7 days post-vaccination and the occurrence of solicited local AE signs and symptoms were collected.

  2. Occurrence of Solicited Systemic AE Signs and Symptoms 7 Days Following the Vaccination [ Time Frame: 7 days following the vaccination ]
    Participants were monitored for 7 days post-vaccination and the occurrence of solicited systemic AE signs and symptoms were collected.

  3. Occurrence of Unsolicited AE 28 Days Following the Vaccination [ Time Frame: 28 days following the vaccination ]
    Occurrence of unsolicited AEs: unsolicited AEs were collected using the patient Diary and reported as "Any AE" occurring 28 days following the vaccination.

  4. Occurrence of Serious AE 24 Weeks Following the Vaccination [ Time Frame: 24 weeks following the vaccination ]
    Occurrence of any treatment - emergent serious AE and treatment - emergent SAE related to study drug was monitored during the study period (24 weeks following vaccination)

  5. Change in Leucocytes From Baseline [ Time Frame: baseline, Weeks 1,2,4,8,12, and 24 ]
  6. Change in Basophils From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  7. Change in Eosinophils From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  8. Change in Neutrophils From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
    Change from baseline was calculated as the value at each week minus the value at the baseline.

  9. Change in Monocytes From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  10. Change in Lymphocytes From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  11. Change in Erythrocytes From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  12. Change in Hematocrit From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  13. Change in Platelets From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  14. Change in Hemoglobin From Baseline [ Time Frame: Weeks 1,2,4,8,12, and 24 ]
  15. Change in Sodium From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  16. Change in Potassium From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  17. Change in Alkaline Phosphatase From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  18. Change in Alanine Aminotransferase From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  19. Change in Aspartate Aminotransferase From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  20. Change in Direct Bilirubin Form Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  21. Change in Bilirubin From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  22. Change in Albumin Form Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  23. Change in Creatinine Form Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  24. Change in Lactate Dehydrogenase From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]
  25. Change in Urea Nitrogen From Baseline [ Time Frame: week 1,2,4,8,12, and 24 ]

Secondary Outcome Measures :
  1. Number of Participants With Positive, Negative or Indeterminate Seroconversion for Anti-s Antibody [ Time Frame: week 1, 2, 4, 8, 12, and 24 ]

    To assess the cellular and humoral immune response to SARS-CoV2 elicited by the vaccine

    Immunogenicity Result: Seroconversion for Anti-S Antibody

    Interpretation: n. of subjects positive, negative or indeterminate at week 1, 2, 4, 8, 12, and 24 after vaccination.


  2. Number of Participants With Positive, Negative Anti-n Antibody [ Time Frame: week 1, 2, 4, 8, 12 and 24 ]

    To assess the cellular and humoral immune response to SARS-CoV2 elicited by the vaccine

    cellular and humoral immune parameters evaluated: anti-N Antibody Interpretation: n. of subjects positive, negative at week 1, 2, 4, 8, 12 and 24 compared to baseline


  3. Number of Participants With Positive, Negative for Micro Neutralization Test [ Time Frame: week 4 and week 24 ]

    To assess the cellular and humoral immune response to SARS-CoV2 elicited by the vaccine cellular and humoral immune parameters evaluated: Micro Neutralization test

    Interpretation: n. of positive and negative subjects at week 4 and week 24 by evaluating geometric mean titer change from baseline


  4. Immunogenicity - T-cell Response [ Time Frame: baseline, week 2, week 4, week 8, week 12, week 24 ]

    To assess the cellular and humoral immune response to SARS-CoV2 elicited by the vaccine cellular and humoral immune parameters evaluated.

    T-cells were evaluated on frozen and fresh (week2) samples

    Within-cohort comparisons to assess the difference in immune response according to different doses in the same population Across-the-cohort comparison to assess whether elderlies and adults have a different pattern of immune response after vaccination at different endpoints

    Unit: spot-forming cells [SFC]/1 × 10^6 peripheral blood mononuclear cell [PBMC]

    Interpretation: values higher than at baseline are indicative of a persistent spike-specific memory T-cell establishment.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

A subject must meet all of the following criteria to be eligible to participate in this study:

  1. Provides written informed consent prior to initiation of any study procedures.
  2. Be able to understand and agrees to comply with planned study procedures and be available for all study visits.
  3. Agrees to the collection of venous blood per protocol.
  4. Confirms to have not donated blood three months before the study
  5. Agrees to refrain from blood during the study and until the three months after the end of the study.
  6. Body Mass Index 18-29 kg/m2, inclusive, at screening.
  7. Premenopausal women must agree to use one acceptable primary form of contraception.
  8. Premenopausal women must have a negative urine pregnancy test the day of vaccination and are routinely using - and willing to use up to six months from vaccine administration - an effective method of birth control resulting in a low failure rate (i.e., hormonal contraception, condoms in combination with a spermicidal cream, male partner sterilization-vasectomy or total sexual abstinence).
  9. Oral temperature ≤37.0 degrees Celsius the day of the administration of the vaccine
  10. Pulse no greater than 100 beats per minute.
  11. Systolic blood pressure (BP) is 85 to 139 mmHg, inclusive the day of vaccination.
  12. Should not show laboratory values outside the normal range which may have clinical significance even in absence of specific signs or symptoms.

Exclusion Criteria:

A subject who meets any of the following criteria will be excluded from participation in this study:

  1. Positive serology for anti-HIV-Ab
  2. Positive HbBsAg
  3. Positive anti-HCV-Ab
  4. Positive for SARS-CoV-2 (either anti-S-Ab or anti-N-Ab)
  5. Acute illness, as determined by the site PI or appropriate sub-investigator, the day of vaccination.
  6. Breastfeeding women
  7. Autoimmune and hyper-inflammatory condition
  8. History of atopy (or any IgE associated condition) who had required treatment over the last 6 months;
  9. History of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction) to any previous licensed or unlicensed vaccines;
  10. Assumption of any immunomodulatory medication over the last 4 months (including, but not limited to, systemic corticosteroids, allergy injections, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs). The use of low dose topical, ophthalmic, inhaled, and intranasal steroid preparations will be permitted.
  11. Presence of self-reported or medically documented significant medical condition
  12. Presence of self-reported or medically documented significant psychiatric condition
  13. Significant cardiovascular disease needing therapy or history of myocarditis or pericarditis or heart surgery. Patients in treatment with Sartans or ACE-Inhibitors and good response to therapy may be included.
  14. Neurological or neurodevelopmental conditions (e.g., history of migraines in the past 5 years, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
  15. Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, which are allowed.
  16. Primary or secondary immunodeficiency of any cause.
  17. Participated in another investigational study involving vaccination of biologic compounds in the last 12 months.
  18. Currently enrolled in or plans to participate in another clinical trial with an investigational agent that will be received during the study-reporting period.
  19. Administration of immunoglobulins and/or any blood or blood products within the 4 months before the first vaccine administration or at any time during the study.
  20. Has any significant disorder of coagulation.
  21. Has any chronic liver disease, including fatty liver.
  22. Has a history of alcohol abuse or other recreational drug use within 6 months before the first vaccine administration.
  23. Has any abnormality or permanent body art (e.g., tattoo) that would interfere with the ability to observe local reactions at the injection site (deltoid region).
  24. Received or plans to receive additional vaccination within 4 weeks before or after each vaccination.
  25. Has been reported as a case (confirmed or probable) of COVID-19 from the regional health system
  26. Has any clinical conditions that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation, this includes any acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04528641


Locations
Layout table for location information
Italy
INMI Spallanzani
Rome, Italy, 00149
Centro Ricerche Cliniche
Verona, Italy, 37134
Sponsors and Collaborators
ReiThera Srl
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Investigators
Layout table for investigator information
Principal Investigator: Simone Lanini Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS
  Study Documents (Full-Text)

Documents provided by ReiThera Srl:
Study Protocol  [PDF] July 30, 2020
Statistical Analysis Plan  [PDF] June 23, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: ReiThera Srl
ClinicalTrials.gov Identifier: NCT04528641    
Other Study ID Numbers: RT-CoV-2
First Posted: August 27, 2020    Key Record Dates
Results First Posted: February 8, 2022
Last Update Posted: February 8, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases